Trial Profile
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Citarinostat (Primary) ; Lenalidomide (Primary) ; Poly ICLC (Primary) ; PVX 410 (Primary)
- Indications Smoldering multiple myeloma
- Focus Adverse reactions
- 12 Apr 2024 Planned End Date changed from 1 Jun 2023 to 15 Sep 2024.
- 12 Apr 2024 Planned primary completion date changed from 1 Jun 2023 to 15 Sep 2024.
- 12 Dec 2023 Trial Design presented at the 65th American Society of Hematology Annual Meeting and Exposition